Neose Technologies, Inc. today provided an update on its clinical development program for NE-180, the Company's long-acting, GlycoPEGylated erythropoietin for the treatment of anemia. The company has concluded the dosing and safety follow-up for its Phase I trial in Western Europe. Final analyses of pharmacokinetic data and other parameters are ongoing. NE-180 was generally well-tolerated at the doses tested, and the expected increases in reticulocytes and hemoglobin were observed in both the intravenous and subcutaneous dose groups.
BioSpace (http://www.biospace.com/news_story.aspx?StoryID=23922&full=1)
